



Professor Roger Taylor, MA, MB, BS, FRCPE, FRCP, FRCR

Present Appointment

Professor of Clinical Oncology
Swansea University

Honorary Consultant in Clinical Oncology,
South West Wales Cancer Centre

Medico-Legal Experience

I have been producing medico-legal reports for the last 25 years averaging 15 – 20 reports per year over the last few years. I am happy to work for both the plaintiff and the defendant and my mix is approximately 60% for plaintiff.

Production of reports has been mainly on cases of brain tumours children's cancer (particularly brain tumours but not leukaemia), sarcoma and lymphoma. I have also been involved in other cases requiring "general oncology" knowledge and experience including radiotherapy toxicity.

I have kept knowledge up to date from literature and conferences in the fields of adult brain tumours, lymphoma, sarcoma (including Ewing's Sarcoma) and many varieties of children's cancer, particularly brain tumours.

Education

1963 – 1970 Bishop Gore School, Swansea


1970 – 1973 University College,

1973 – 1976 St.Bartholomew's Hosp.Med.Coll. 1973-1976

Qualifications: B.A. (Oxon.) Physiological Sciences 1973
M.A. (Oxon.) 1979
M.B.,B.S. (London) Nov. 1976
M.R.C.P. (U.K.) March 1979
F.R.C.R. (Radiotherapy and Oncology) Nov. 1984
F.R.C.P. (Edin.) July 1992
F.R.C.P. (Lond.) July 1998



contact@cancerlegalexperts.co.uk



Previous posts:

Consultant Clinical Oncologist,
Cookridge Hospital, Leeds.

Honorary Senior Clinical Lecturer,
Research School of Medicine, University of Leeds.

Summary of publications

My publication record spans over three decades and reflects a sustained contribution to clinical and paediatric oncology, with a primary focus on radiotherapy for childhood cancers, particularly central nervous system tumours, medulloblastoma, and Wilms' tumour. Early work addressed adult malignancies including testicular germ-cell tumours, lymphoma, bladder and breast cancer, contributing to improved understanding of chemotherapy, radiotherapy outcomes, imaging, and biomarkers.

From the mid-1990s onwards, research centred on paediatric neuro-oncology, with major involvement in national and international multicentre trials through the UKCCSG and SIOP, including the PNET-3 and PNET-4 studies. These publications helped define standards of care, optimise radiotherapy dose and volume, and clarify patterns of relapse and late effects.

Subsequent work has advanced molecular risk stratification of medulloblastoma and the clinical development of proton beam therapy, including consensus statements and systematic reviews. The portfolio also includes influential reviews, editorials, and service guidance, demonstrating leadership in paediatric radiotherapy and clinical trial collaboration.

References

Available upon request

